SEC Form 4 · accession 0001209191-15-047289
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. Butler
Officer — CEO and President · Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 6:31 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 26, 2015 | M | 50,000 | $0.47 | A | 198,350 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.47 | May 26, 2015 | M | 50,000 | D | — | Sep 16, 2023 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II. This option was granted on September 16, 2013. Twenty-five percent vested on September 16, 2014 with the remaining seventy-five percent vesting in equal monthly installments thereafter until fully vested on September 1, 2017.